OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology

OMass announced a Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. GV participated as an existing investor. Proceeds support clinical development of its endocrinology and immunology portfolio.